124 related articles for article (PubMed ID: 15515571)
21. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
[TBL] [Abstract][Full Text] [Related]
22. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.
Jagarlamudi KK; Shaw M
Biomark Med; 2018 Sep; 12(9):1035-1048. PubMed ID: 30039979
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma.
Lehtinen T; Aine R; Kellokumpu-Lehtinen P; Hakala T; Lehtinen M
Acta Oncol; 1993; 32(7-8):779-81. PubMed ID: 8305226
[TBL] [Abstract][Full Text] [Related]
24. Serum thymidine kinase 1 and C-reactive protein as biomarkers for screening clinically healthy dogs for occult disease.
Selting KA; Sharp CR; Ringold R; Knouse J
Vet Comp Oncol; 2015 Dec; 13(4):373-84. PubMed ID: 23859156
[TBL] [Abstract][Full Text] [Related]
25. Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.
Selting KA; Ringold R; Husbands B; Pithua PO
J Vet Intern Med; 2016 Jul; 30(4):1159-66. PubMed ID: 27214230
[TBL] [Abstract][Full Text] [Related]
26. Elevation of serum thymidine kinase 1 in a bacterial infection: canine pyometra.
Sharif H; Hagman R; Wang L; Eriksson S
Theriogenology; 2013 Jan; 79(1):17-23. PubMed ID: 23102844
[TBL] [Abstract][Full Text] [Related]
27. Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma.
Larsdotter S; Nostell K; von Euler H
Vet J; 2015 Aug; 205(2):313-6. PubMed ID: 25744802
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic value of serum lactate dehydrogenase (LDH) and LDH isoenzymes in canine lymphoma.
Zanatta R; Abate O; D'Angelo A; Miniscalco B; Mannelli A
Vet Res Commun; 2003 Sep; 27 Suppl 1():449-52. PubMed ID: 14535451
[No Abstract] [Full Text] [Related]
29. RNA-dependent DNA polymerase activity in canine lymphosarcoma.
Onions D
Eur J Cancer (1965); 1980 Mar; 16(3):345-50. PubMed ID: 6154578
[No Abstract] [Full Text] [Related]
30. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
Boyé P; Serres F; Floch F; Fournel-Fleury C; Tierny D
Vet Comp Oncol; 2021 Mar; 19(1):44-52. PubMed ID: 32643242
[TBL] [Abstract][Full Text] [Related]
32. Endothelial area and microvascular density in a canine non-Hodgkin's lymphoma: an interspecies model of tumor angiogenesis.
Ranieri G; Patruno R; Lionetti A; Di Summa A; Mattioli E; Bufo P; Pellecchia A; Ribatti D; Zizzo N
Leuk Lymphoma; 2005 Nov; 46(11):1639-43. PubMed ID: 16236617
[TBL] [Abstract][Full Text] [Related]
33. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
Lehtinen T
Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
[TBL] [Abstract][Full Text] [Related]
34. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation.
Gatt ME; Goldschmidt N; Kalichman I; Friedman M; Arronson AC; Barak V
Anticancer Res; 2015 May; 35(5):3019-26. PubMed ID: 25964590
[TBL] [Abstract][Full Text] [Related]
35. Hodgkin's disease-like lesions in the dog.
Wells GA
J Pathol; 1974 Jan; 112(1):5-10. PubMed ID: 4406958
[No Abstract] [Full Text] [Related]
36. Microvascular density and endothelial area correlate with Ki-67 proliferative rate in the canine non-Hodgkin's lymphoma spontaneous model.
Patruno R; Zizzo N; Zito AF; Catalano V; Valerio P; Pellecchia V; D'Errico E; Mazzone F; Ribatti D; Ranieri G
Leuk Lymphoma; 2006 Jun; 47(6):1138-43. PubMed ID: 16840207
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
Silver M; Rusk A; Phillips B; Beck E; Jankowski M; Philibert J; Hahn K; Hershey E; McKeegan E; Bauch J; Krivoshik A; Khanna C
J Vet Intern Med; 2012; 26(2):349-54. PubMed ID: 22369215
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma.
Hahn KA; Richardson RC; Hahn EA; Chrisman CL
Vet Pathol; 1994 Sep; 31(5):528-40. PubMed ID: 7801430
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia.
Stelmach P; Błoński JZ; Wawrzyniak E; Schweiger PE; Wilandt A; Majak PE; Robak T
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1321-1330. PubMed ID: 28100842
[TBL] [Abstract][Full Text] [Related]
40. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
